Preclinical Blood Test IDs Risk for Respiratory Death, Incident COPD
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 11, 2024 -- A proteomic signature indicating increased respiratory susceptibility identifies the risk for respiratory death, incident chronic obstructive pulmonary disease (COPD), and respiratory exacerbations, according to a study published online Sept. 10 in the American Journal of Respiratory and Critical Care Medicine.
Gabrielle Y. Liu, M.D., from the UC Davis School of Medicine in Sacramento, California, and colleagues examined whether a proteomic risk score trained on accelerated decline in lung function can predict the risk for future respiratory disease and mortality in CARDIA, a population-based cohort starting in young adulthood. To identify accelerated and normal decline trajectories, longitudinal measurement of forced expiratory volume in 1 second percent predicted was used. Protein aptamers associated with an accelerated decline trajectory were identified. The proteomic respiratory susceptibility score was derived based on these circulating proteins and applied to the U.K. Biobank and COPDGene.
The researchers found an independent association for a higher susceptibility score with all-cause mortality (hazard ratios [HR], 1.56 and 1.75 in the U.K. Biobank and COPDGene); respiratory mortality (HR, 2.39 and 1.81 in the U.K. Biobank and COPDGene); incident COPD (HR, 1.84 in the U.K. Biobank); incident respiratory exacerbation (odds ratio [OR], 1.10 in COPDGene); and incident exacerbation requiring hospitalization (OR, 1.17 in COPDGene).
"The proteins identified in this study show promise as biomarkers for impaired respiratory health. Further study to elucidate their utility as modifiable targets for the prevention and interception of chronic lung disease in at-risk populations is warranted," the authors write.
The COPDGene study is funded by contributions from several pharmaceutical companies.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
American College of Chest Physicians, Oct. 6-9
The annual meeting of the American College of Chest Physicians was held this year from Oct. 6 to 9 in Boston, hosting participants from around the world, including...
CHEST: Dupilumab for COPD Tied to Improvement in Health-Related Quality of Life
MONDAY, Oct. 7, 2024 -- Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according...
FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease
TUESDAY, Oct. 1, 2024 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.